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Letters to the Editormigrated into the left ventricle.
Because of hemodynamic instability,
our cardiac surgery team intervened
locally and placed the patient on
extracorporeal membrane oxygena-
tion, before transferring her to our
institution, where she underwent
aortic valve replacement. After a
complicated course, she was sent to
a rehabilitation facility in good
condition.
During the late 1980s and the
beginning of the 1990s, at the onset
of the coronary interventional era, all
procedures were performed only in in-
stitutions with cardiac surgery on site
and strictly with surgical standby.
Later, with the increasing confidence
of the interventional cardiologists,
more sophisticated technology, and a
very low need for surgical rescue,
the procedure also gained widespread
application in hospitals without car-
diac surgery on site.
Similarly, because the need for sur-
gical rescue has been low in all series,
it is understandable that some inter-
ventional cardiologists have been
tempted to perform TAVI without sur-
gical standby. Approximately one
third of centers performing TAVI in
Germany do not have cardiac surgery
on site, and in Italy, at least 1 other
institution currently performs TAVI
without cardiac surgery on standby.
Not surprisingly, the invasive cardi-
ologists are already in turmoil, and the
discussion on whether TAVI can be
performed without on-site cardiac sur-
gery has been continuing in the pub-
lished studies. In response to a plea
for a same-institution interdisci-
plinary approach,2 Eggebrecht and
colleagues3 cautioned against consid-
ering the use of the heart team concept
as being synonymous with an on-site
cardiac surgery program. They also
claimed that some centers have
embraced a different ‘‘heart team’’
interpretation by collaborating with
cardiac surgeons who would come to
their hospitals, participate in the pro-
cedure, and rescue the patient when
complications occurred.3542 The Journal of Thoracic and CThrough our experiencewith the pa-
tient we have described, others would
now argue that, provided the expertise
is available to promptly institute extra-
corporealmembrane oxygenation, this
could be another acceptable method to
salvage patients with complicated
cases. Finally, let us not forget that
the entire dispute could become
merely academic if someone asked
why bother to try to rescue, with slight
chances of success, that very rare pa-
tient already deemed inoperable by
the surgeon from the beginning. Our
patient’s good outcome was probably
more the exception than the rule.
Notwithstanding any of these argu-
ments, we and the surgical community
remain convinced that to achieve the
best possible result, any major
complication should be managed by
a surgical team immediately after the
occurrence and that any other creative
arrangements can only put the pa-
tient’s life at greater risk and subject
the hospital and operating team to a
malpractice suit. That statement be-
comes even more persuasive if we
look at the future, when this procedure
could be offered to an increasing num-
ber of patients who are low-risk surgi-
cal candidates.
Accordingly, the recent European
Society of Cardiology/European As-
sociation for Cardio-Thoracic Surgery
guidelines4 have considered the
absence of cardiac surgery on site a
contraindication. Hopefully, also in
Europe and Italy, just as in the United
States, procedure reimbursement will
be authorized only for those institu-
tions at which TAVIs are performed
in an interventional suite or hybrid
operating room by a heart team.
Only then we could consider applying
this revolutionary procedure even in
lower risk patients.
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To the Editor:
It was with great interest that we
read the article by Heinz and col-
leagues1 reporting the long-term out-
comes after Freestyle (Medtronic
Inc, Minneapolis, Minn) root replace-
ment for complex destructive aortic
valve endocarditis. They included 32
patients (median age, 61 years) who
underwent the procedure between
1997 and 2012 and found that 5-year
survival was 62%, and 5-year
freedom from short- and long-term
cardiac events was 56%. They
concluded that the Freestyle xenograft
is a comparable alternative to homo-
graft for treatment of complex aortic
valve endocarditis.
We congratulate Heinz and col-
leagues on their excellent results in a
challenging patient group and we
wish to offer some additional data
supporting the use of the Freestyle
FIGURE 1. Kaplan-Meier estimated survival in 25 patients who underwent Freestyle (Medtronic
Inc, Minneapolis, Minn) xenograft aortic valve replacement for infective endocarditis between
2002 and 2012.
Letters to the Editorgraft in the treatment of infective
aortic valve endocarditis.
We investigated long-term survival
after surgical intervention for native
and prosthetic valve endocarditis.2
Our total study population consisted
of 252 patients, 25 of whom received
a Freestyle xenograft. The median
age was 57 years (range, 24-73
years); 16 were men and 9 were
women. Fifteen patients (60%) had
prosthetic valve endocarditis and 10
patients (40%) had native valve en-
docarditis. Death within 30 days of
surgery occurred in 4 patients
(16%). One- and 5-year survival
was 76% and 65%, respectively
(Figure 1). Five-year survival was
70% in patients who were operated
on for native valve endocarditis and
53% in patients who underwent pros-
thetic valve endocarditis; however,
the survival difference was not statis-
tically significant. Five-year survival
was 69% in the 16 patients in our
original study population who
received a homograft.
Promising results were also re-
ported in an Italian study3 of 18 pa-
tients who underwent aortic root
replacement for infective endocarditis
with a Freestyle xenograft. The in-The Journalhospital mortality was 11%, and dur-
ing a median follow-up time of 24
months (range, 1-113 months) no
deaths occurred. Furthermore,
freedom from reoperation was 87.5%.
Thus, the results from our study2
and the Italian study3 are in accor-
dance with the findings from Heinz
and colleagues.1 We therefore agree
with the authors’ conclusion that
the Freestyle xenograft can be
considered a reliable choice for pa-
tients with aortic valve infective en-
docarditis in need of aortic root
replacement.
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The letter by Edlin and Sartipy
adds further important information
on the advantages of the Freestyle
xenograft in aortic valve endocardi-
tis. Their results are excellent, and
we congratulate them. Fifteen of
their patients (60%) had prosthetic
valve endocarditis, and the indication
for full root replacement thus ap-
pears obvious.1 For the remaining
10 cases, however, they gave no in-
formation on extent of the disease
and mode of use of the xenograft
(full root vs subcoronary technique).
This information would be of major
importance for adequate appreciation
of the results. Nonetheless, their
results do reflect our conclusion
that homograft use can be safely re-
placed with xenograft use for this
indication.2
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